Unichem Labs under regulator scanner for launching blood pressure medicines without price approval - (The Economic Times via NewsPoints Desk)

  • Unichem Laboratories is being probed by India's National Pharmaceutical Pricing Authority (NPPA) for allegedly launching six hypertension drugs before receiving price approval, as reported The Economic Times Tuesday.

  • The NPPA will also ask India's drug regulator to clarify whether the drugs, which were marketed under the Tritelsar and Triolsar brands, have therapeutic value.

  • The agency contends that Unichem did not request price fixation for the drugs until December 2017 despite launching them in 2013.

  • The NPPA is expected to determine a penalty for overcharging for the drugs as well as set new retail prices for the products by its next meeting.

  • A spokesperson for Torrent Pharmaceuticals, which recently agreed to purchase Unichem's Indian business for Rs. 3600 crore, said the drugmaker has not received a notice from the NPPA regarding the issue.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.